Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Reuters

BioNTech Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Why BioNTech Shares Are Surging Today

BioNTech SE (NASDAQ:BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE:PFE) delivered approximately 2.6 billion doses of Comirnaty/BNT162b2 worldwide in 2021, including over 1 billion doses to low- and middle-income countries. As…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech Stock Pops On Soaring Earnings, $1.5 Billion Share Buyback

BioNTech stock jumped Wednesday after the company's earnings easily beat forecasts, and after it announced a $1.5 billion share buyback plan.

Investors Business Daily

Recap: BioNTech Q4 Earnings

BioNTech (NASDAQ:BNTX) reported its Q4 earnings results on Wednesday, March 30, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga

Dow Jones Dips Amid Strong Market Rally; Apple, SolarEdge, Micron In Focus

Futures signaled a lower open for the Dow Jones today, but the market rally is strong. Apple and Dutch Bros are in buy zones.

Investors Business Daily

BioNTech's quarterly profit soars on COVID-19 vaccine demand

BioNTech has reported another quarter of strong earnings growth

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Moderna, BioNTech Pop After FDA OKs Another Covid Booster Round — But Not For Everyone

Vaccine stocks jumped Tuesday after the FDA authorized another round of Covid booster shots for people age 50 and older.

Investors Business Daily

Stock Market Gains As Consumer Confidence Rises; Techs Rise; Vaccine Stocks Pop

The stock market gained as consumer confidence rose, peace talks resumed between Russia and Ukraine and vaccine stocks popped.

Investors Business Daily

Earnings Outlook For BioNTech

BioNTech (NASDAQ:BNTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement. Analysts estimate that BioNTech will report an earnings per share (EPS) of $8.19.

Benzinga

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Key takeaways:

Benzinga

Overview Of Value Stocks In The Healthcare Sector

What are Value Stocks?

Benzinga

Fosun Reports $157 Million of China mRNA Vaccine Sales in 2021

BioNTech partner markets the advanced-tech inoculation in Hong Kong, Macao and Taiwan as regulators haven’t cleared the shots for the mainland

Caixin Global

How Moderna Could Sneak By Pfizer, BioNTech With A Pediatric Covid Vaccine

Moderna stock tumbled Wednesday despite promising test results that could help it beat Pfizer to the finish line with a pediatric Covid shot.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

No funds to buy fourth Covid vaccine dose for all Americans, White House warns

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

Investors Business Daily

How Long Will Moderna, BioNTech Tread Water During Endemic Covid?

The FDA will discuss Covid booster shots from Pfizer and Moderna next month — possibly giving vaccine stocks another chance to shine.

Financial Times

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100’s of premium titles.
One news app.

Asharq Al-Awsat

Pfizer-BioNTech Seek US Approval of Second Covid Booster for 65+

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older. The companies said in a press statement that their request is based off two Israeli studies that show…

Axios

Pfizer and BioNTech plan to seek authorization for second COVID booster for people 65 and up

The move is an attempt to bolster waning immunity that occurs several months after a first booster shot.

Benzinga

Here's Why BioNTech Shares Are Rising On Monday

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

The Conversation

How drug companies are sidestepping the WHO's technology transfer hub in Africa

Pharmaceutical company Moderna announced on 7 March 2022 that it would develop a site in Kenya to manufacture COVID-19 vaccines. The company holds much of the key intellectual property relating to the messenger RNA (mRNA) vaccines. Due to their higher efficacy, mRNA vaccines are the preferred option in developed countries.…

Investors Business Daily

Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care

Vaccine stocks popped Wednesday, but remain broadly under pressure. Their Covid wares are predicted to fall as the virus becomes endemic.

Benzinga

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Benzinga

Where BioNTech Stands With Analysts

BioNTech (NASDAQ:BNTX) has observed the following analyst ratings within the last quarter:

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.